The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy)

Inclusion Criteria: * History of stable or unstable angina * LVEF \> 35% on transthoracic echocardiography measurement * Single lesion occluding the coronary artery detected by angiography or MSCTA, with or without stenosis of other coronary arteries (≤ 50% stenotic lesion) * Availability for follow-up for up to 12 months * No major barriers to provide written consent Exclusion Criteria: * Acute Q-wave myocardial infarction during the latest 3 months * Revascularization in the non-culprit artery during the latest one month * Unsuitable for PCI * Unable to tolerate dual antiplatelet treatment (DAPT) * Severe abnormal hematopoietic system, such as platelet count of \< 100×109/L or \> 700×109/L and white blood cell count of \< 3×109/L * Active bleeding or bleeding tendency * Severe coexisting conditions, such as severe renal insufficiency (GFR \< 60 ml/min•1.73m2), severe hepatic dysfunction \[elevated ALT (glutamic-pyruvic transaminase) or AST (glutamic-oxal acetic transaminase) level by more than three-fold of the normal limitation\], acute or chronic heart failure (NYHA III-IV), acute infectious diseases, immune disorders, malignancy, etc. * Life expectancy \< 12 months * Pregnancy or planning pregnancy * Drug allergies or contraindications to aspirin, clopidogrel, ticagrelor, statins, contract, anticoagulant, stent, etc. * Participation or planning to participate in another clinical trial during the same period * Refusal to comply with the study protocol